New Insights into the Use of Direct Oral Anticoagulants in Non-high Risk Thrombotic APS Patients: Literature Review and Subgroup Analysis from a Meta-analysis-Reference-Cited by-同舟云学术

New Insights into the Use of Direct Oral Anticoagulants in Non-high Risk Thrombotic APS Patients: Literature Review and Subgroup Analysis from a Meta-analysis

Published:2020-05-20 Issue:7 Volume:22 Page:
ISSN:1523-3774
Container-title:Current Rheumatology Reports
language:en
Short-container-title:Curr Rheumatol Rep

Author:

Dufrost Virginie,Darnige Luc,Reshetnyak Tatiana,Vorobyeva Maria,Jiang Xin,Yan Xin-xin,Gerotziafas Grigorios,Jing Zhi-Cheng,Elalamy Ismaël,Wahl Denis,Zuily Stéphane

Publisher

Springer Science and Business Media LLC

Subject

Rheumatology

Link

https://link.springer.com/content/pdf/10.1007/s11926-020-00901-y.pdf

Reference21 articles.

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.

2. Erkan D, Aguiar CL, Andrade D, Cohen H, Cuadrado MJ, Danowski A, et al. 14th international congress on antiphospholipid antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13(6):685–96.

3. •• Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132(13):1365–71. This trial showed that DOACs in not safe in APS patients with triple positivity.

4. Cohen H, Hunt BJ, Efthymiou M, Arachchillage DRJ, Mackie IJ, Clawson S, et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol. 2016;3(9):e426–36.

5. •• Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, Vidal X, Riera-Mestre A, Castro-Salomó A, et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med. 15 oct 2019; https://doi.org/10.7326/M19-0291. This trial suggests that rivaroxaban could not prevent arterial thrombosis especially in patients with a history of arterial thrombosis.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thrombotic antiphospholipid syndrome: Recurrent thromboses;Rheumatology Science and Practice;2024-09-02

2. Anticoagulation in Pediatric Patients;Techniques in Vascular and Interventional Radiology;2024-06

3. Anticoagulantes de acción directa en el síndrome antifosfolípido. Revisión sistemática;Medicina Clínica;2023-07

4. Direct-acting oral anticoagulants in antiphospholipid syndrome: A systematic review;Medicina Clínica (English Edition);2023-07

5. Comparing the efficacy and safety of direct oral anticoagulants versus Vitamin K antagonists in patients with antiphospholipid syndrome: a systematic review and meta-analysis;Blood Coagulation & Fibrinolysis;2022-07-22